The divestment agreement includes all patents, patent applications and associated biological material that forms the basis of the development project. The purchase consideration amounted to SEK 2.0 M, of which SEK 0.5 M was paid in conjunction with the signing of the agreement, with the remaining SEK 1.5 M due for payment when Evy Lundgren-Åkerlund’s company receives revenues attributable to the patents, patent applications or associated biological material. As of the date on which the agreement was signed, the costs and responsibilities for ensuring that all patents and patent applications in the alpha-10 project are upheld rest with Evy Lundgren-Åkerlund’s company.“Alpha-10/beta-1 is a surface protein that is only expressed by the cells that are directly responsible for the formation of cartilage tissue, chondrocytes. Theoretically, this specific expression makes alpha-10 an attractive drug target. However, at Hansa Medical, we focus on projects whose therapeutic potential has been proven, such as alpha-11, IdeS and EndoS. Because the alpha-10 research project is at a very early stage and its therapeutic effects have not yet been proven, we have decided to sell the project to the discoverer of the alpha-10/beta-1 integrin, Evy Lundgren-Åkerlund,” says Hansa Medical’s CEO, Emanuel Björne.The Hansa Medical share is traded on First North under the ticker symbol HMED, and the company’s certified adviser is Remium AB.For more information, please contact:Emanuel Björne, CEOMobile: +46 707 17 54 77E-mail: emanuel.bjorne@hansamedical.com Evy Lundgren-ÅkerlundTelephone: +46 703 29 18 71E-mail: evy.akerlund@gmail.com